


Novel Indolethylbenzamides for the Treatment of Tauopathies

Patent Highlight


Gerard Rosse^{*,†}

Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121

Title:	Novel Indolethylbenzamides for the Treatment of Tauopathies		
Patent/Patent Application Number:	WO 2012080221, A1	Publication date:	June 21, 2012
Priority Application:	GB 2010-21103	Priority date:	December 13, 2011
Inventors:	Griffioen, G.; Van Dooren, T.; Rojas de la Parra, V.; Marchand, A.; Allasia, S.; Kilonda, A.; Chaltin, P.		
Assignee Company:	Katholieke Universiteit Leuven, Belgium		
Disease Area:	Neurodegenerative disorder	Biological Target:	Tau and/or α -synuclein
Summary:	This invention provides a novel series of indolethylbenzamides which efficiently inhibit the Tau-aggregation induced toxicity. This class of compounds is useful for preventing or treating neurodegenerative disorders, especially tauopathies, including Alzheimer's disease and Parkinson's disease.		
Important Compound Classes:			



Key Structures:



Recent Review Articles:

1. Navarrete, L. P.; Perez, P.; Morales, I.; Maccioni, R. B. Novel drugs affecting Tau behavior in the treatment of Alzheimer's disease and tauopathies. *Curr. Alzheimer Res.* **2011**, *8* (6), 678–685.
2. Bulic, B.; Pickhardt, M.; Mandelkow, E.-M.; Mandelkow, E. Tau protein and Tau aggregation inhibitors. *Neuropharmacology* **2010**, *59* (4–5), 276–289.

Biological Assays

Inhibition of Tau cytotoxicity using a M17-TAU P301L cell line. Inhibitors of Tau cytotoxicity were found to inhibit LDH leakage of M17-TAU P301L cell as described.

In vivo inhibition of pathological Tau-phosphorylation.

α -Synuclein expressing cells as a model for neuronal degradation.

In vivo inhibition of α -synuclein aggregation.

Special Issue: Alzheimer's Disease

Published: October 24, 2012

Pharmacological Data:	90 compounds tested in Tau-induced toxicity experiments. Selected examples are described above.
Synthesis:	Preparation of 117 compounds.
Claims:	Claims 16–17: Use of compounds for the treatment of a variety of diseases, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and ALS.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: grosse@dartneuroscience.com.

†Present address: Adjunct Associate Professor, Department of Pharmacology and Physiology, Drexel University, College of Medicine, New College Building, 245 N. 15th Street, Philadelphia, PA 19102.

Notes

The authors declare no competing financial interest.